Ann-Sofie Backman is an associate professor at the Karolinska Institute, and senior consultant in Gastroenterology at Ersta hospital, Stockholm. She is the coordinating investigator in the MesaCapp trial, an academic double-blinded trial investigating the chemopreventive potential in mesalamine in Lynch syndrome. Mesalamine is a well known drug for inflammatory bowel disease with anti-inflammatory properties. She performs endoscopies, treat GI-disorders and her research focus on inflammation and early detection and/or prevention of cancer in the gut.
In her lecture this year, Dr. Backman will give an update on mesalamine-based chemoprevention of colorectal cancer.